West Pharmaceutical Services, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Deborah L. V. Keller

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Deborah L. V. Keller”): 57,992,162 for, 5,599,392 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 24,680,188 for, 387,798 against, 2,850 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Douglas A. Michels

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Douglas A. Michels”): 60,240,141 for, 3,670,807 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 24,693,731 for, 374,257 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Eric M. Green

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Eric M. Green”): 58,892,532 for, 4,573,928 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 24,724,216 for, 343,768 against, 2,851 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Janet B. Haugen

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Janet B. Haugen”): 61,934,409 for, 1,987,189 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 25,067,975 for, 13 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Mark A. Buthman

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Mark A. Buthman”): 62,394,975 for, 1,521,106 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 25,050,327 for, 17,661 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Molly E. Joseph

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Molly E. Joseph”): 61,545,956 for, 2,341,355 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 24,711,392 for, 356,596 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Myla P. Lai-Goldman

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Myla P. Lai-Goldman”): 61,523,642 for, 2,395,041 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 25,050,321 for, 17,667 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Robert F. Friel

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Robert F. Friel”): 62,396,755 for, 1,521,677 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 24,711,399 for, 356,588 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Stephen H. Lockhart

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Stephen H. Lockhart”): 63,432,380 for, 470,840 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 25,030,096 for, 37,892 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: William F. Feehery

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: William F. Feehery”): 61,427,391 for, 2,489,202 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 142 asset managers below reported 25,050,320 for, 17,667 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

Description as filed by funds: Election of Directors: Paolo Pucci

West Pharmaceutical Services, Inc.’s own tally for this item (“Elect Director: Paolo Pucci”): 62,930,048 for, 981,152 against, per its Form 8-K filed May 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 141 asset managers below reported 25,039,996 for, 17,642 against, 2,847 abstained, 55 not voted.

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.

Description as filed by funds: Advisory vote to approve named executive officer compensation.

West Pharmaceutical Services, Inc.’s own tally for this item (“2. Non-binding advisory vote to approve the compensation of the Company's named executive officers”): 60,107,802 for, 3,762,206 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The non-binding advisory vote to approve the compensation of the Company's named executive officers was approved as set forth below.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 139 managers: 24,995,602 for, 45,264 against, 1,420 abstained, 55 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 594 managers: 39,796,204 for, 3,446,124 against, 1,593 abstained, 8,357 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of our independent registered public accounting firm for 2026.

West Pharmaceutical Services, Inc.’s own tally for this item (“3. Appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year”): 58,509,119 for, 7,556,514 against — passed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified as set forth below.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 140 asset managers below reported 24,892,468 for, 153,749 against, 1,420 abstained, 55 not voted.

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

Description as filed by funds: Shareholder proposal regarding an independent Board Chair policy.

West Pharmaceutical Services, Inc.’s own tally for this item (“4. Shareholder proposal regarding an Independent Board Chair Policy”): 29,592,488 for, 34,245,125 against — failed, per its Form 8-K filed May 5, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “Proposal 4: The shareholder proposal regarding an Independent Board Chair Policy was not approved as set forth below.”
Support: 46.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 141 asset managers below reported 7,201,391 for, 17,857,674 against, 1,420 abstained, 55 not voted.

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.